INGREZZA FDA approval & 9 more major updates...
Want a list of segmented biopharma companies or access to our online platform? Get more info about our data and how it can help with sales and market intelligence
🎯 → Approvals
🔬 → New data
🤝 → M&A activity
Neurocrine Biosciences
🎯 Received FDA approval of INGREZZA® SPRINKLE (valbenazine) capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.
Pfizer
🎯 FDA approved TIVDAK® treating recurrent or metastatic cervical cancer.
Aquestive Therapeutics
🎯 Received FDA approval for Libervant™ (diazepam) buccal film treating seizure clusters in children aged two to five years.
X4 Pharmaceuticals
🎯 FDA approved of XOLREMDI™ (mavorixafor) treating patients with WHIM syndrome.
Vertex Pharmaceuticals
🎯 Received EC approval for KALYDECO® to treating infants with cystic fibrosis for ages 1 month and older.
Merck
🔬 Reported results from the Ph3 KEYNOTE-811 trial evaluating KEYTRUDA® + trastuzumab + fluoropyrimidine- and platinum-containing chemotherapy meeting its dual primary endpoint of overall survival (OS) in patients with HER2-positive advanced gastric or GEJ adenocarcinoma
🔬 Data reported from the STRIDE-10 Ph3 trial evaluating V116, an Investigational, 21-valent Pneumococcal conjugate vaccine for adults eliciting significant immune response and good safety profile.
Sellas Life Sciences
🔬 Reported Ph2 preliminary data of SLS009 in r/r AML achieving a 100% response rate in patients with ASXL1 mutation at the optimal dose level.
Senti Bio
🔬 Published SENTI-202preclinical data showing the potential of logic-gated CAR-NK Cell therapy for treating AML.
Astellas & Poseida Therapeutics
🤝 Initiated research collaboration and license agreement to develop novel allogeneic cell therapies in oncology.
Deciphera Pharmaceuticals & ONO Pharmaceutical
🤝 Ono Pharmaceutical to acquire Deciphera Pharmaceutical for $2.4B.
Akari Therapeutics & Peak Bio
🤝 Completed the portfolio prioritization plan as part of the imminent merger focusing on Peak’s antibody-drug conjugate (ADC) technology.
---
Interested in these updates? Get the full update each week → https://www.biopharmiq.com/#subscribe
Data:
April 29-May 3, 2024
Article History:
RF, DV, DG (05/6/24)
Комментарии